Avantax Advisory Services Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS – Get Rating) by 4.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,448 shares of the company’s stock after buying an additional 179 shares during the period. Avantax Advisory Services Inc.’s holdings in Zoetis were worth $660,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of ZTS. Arrowstreet Capital Limited Partnership lifted its holdings in Zoetis by 171.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock worth $627,335,000 after buying an additional 2,102,306 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Zoetis by 46.8% during the second quarter. JPMorgan Chase & Co. now owns 2,310,781 shares of the company’s stock valued at $397,198,000 after purchasing an additional 736,720 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Zoetis by 359.6% during the first quarter. Renaissance Technologies LLC now owns 922,274 shares of the company’s stock valued at $173,932,000 after purchasing an additional 721,600 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Zoetis by 240.6% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 940,581 shares of the company’s stock valued at $139,479,000 after purchasing an additional 664,410 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Zoetis by 21.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,999,335 shares of the company’s stock valued at $565,645,000 after purchasing an additional 527,760 shares during the last quarter. 90.23% of the stock is currently owned by hedge funds and other institutional investors.
Zoetis Trading Up 1.1 %
NYSE:ZTS opened at $163.81 on Monday. The company has a current ratio of 2.27, a quick ratio of 1.48 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 12 month low of $124.15 and a 12 month high of $205.30. The company has a market cap of $76.35 billion, a PE ratio of 37.40, a price-to-earnings-growth ratio of 2.82 and a beta of 0.73. The company has a 50 day simple moving average of $150.72 and a two-hundred day simple moving average of $156.81.
Zoetis Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, January 20th will be given a $0.375 dividend. This represents a $1.50 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Thursday, January 19th. This is an increase from Zoetis’s previous quarterly dividend of $0.33. Zoetis’s payout ratio is 34.25%.
Wall Street Analysts Forecast Growth
ZTS has been the subject of several recent research reports. The Goldman Sachs Group lowered their target price on shares of Zoetis from $207.00 to $180.00 and set a “buy” rating for the company in a report on Friday, November 4th. Morgan Stanley lowered their target price on shares of Zoetis from $264.00 to $248.00 and set an “overweight” rating for the company in a report on Tuesday, November 15th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Thursday, November 3rd. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $250.00 to $225.00 and set an “overweight” rating for the company in a report on Monday, October 17th. Finally, StockNews.com began coverage on shares of Zoetis in a research report on Wednesday, October 12th. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and an average target price of $215.17.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.